Trevena Presents Preclinical Data for TRV120027, a Biased AT1R Ligand, at the 14th Annual Heart Failure Society of America Meeting Sep 13, 2010 7:00am EDT
Trevena Secures $35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure Jul 14, 2010 7:00am EDT
Trevena Data Showcasing GPCR Biased Ligands Featured at Scientific Conferences Jun 11, 2010 8:00am EDT
Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand Apr 14, 2010 8:00am EDT
Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development Feb 08, 2010 8:00am EST
Trevena Scientific Co-Founder and Scientific Advisory Board Member Honored with 2009 BBVA Foundation Frontiers of Knowledge Award Feb 03, 2010 8:00am EST
Trevena Awarded $7.65 Million NIH Grant to Accelerate Identification and Selection of Biased GPCR Ligands Nov 03, 2009 7:00am EST
Trevena, Inc. Named by BusinessWeek as One of the "Most Successful U.S. Startups 2008" Jan 05, 2009 8:00am EST
